A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in  -thalassemia major (CORDELIA)

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

(2012) Elena Cassinerio et al.   ANNALS OF HEMATOLOGY

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

On T2* Magnetic Resonance and Cardiac Iron

(2011) John-Paul Carpenter et al.   CIRCULATION

Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial

(2010) John C. Wood et al.   AMERICAN JOURNAL OF HEMATOLOGY

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Continued improvement in myocardial T2* over two years of deferasirox therapy in  -thalassemia major patients with cardiac iron overload

(2010) D. J. Pennell et al.   HAEMATOLOGICA

Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies

(2010) John B. Porter et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers

(2010) Paul Kirk et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Efficacy of deferasirox in reducing and preventing cardiac iron overload in  -thalassemia

(2009) D. J. Pennell et al.   BLOOD

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Longitudinal analysis of heart and liver iron in thalassemia major

(2008) L. J. Noetzli et al.   BLOOD

Onset of cardiac iron loading in pediatric patients with thalassemia major

(2008) J. C. Wood et al.   HAEMATOLOGICA